Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+status: Updated results from the phase 3 IKEMA study.

被引：0
|
作者：
Facon, Thierry
Moreau, Philippe
Spicka, Ivan
Suzuki, Kenshi
Yong, Kwee
Mikhael, Joseph
Fukao, Taro
Bisht, Kamlesh
Armstrong, Nicole
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas G.
机构：
[1] Lille Univ Hosp, Dept Hematol, Lille, France
[2] Univ Hosp Nantes, Dept Hematol, Nantes, France
[3] Charles Univ Prague, Gen Fac Hosp, Prague, Czech Republic
[4] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[5] Japanese Red Cross Med Ctr, Myeloma Amyloidosis Ctr, Tokyo, Japan
[6] Univ Coll Hosp, Dept Haematol, London, England
[7] City Hope Canc Ctr, Translat Genom Res Inst, Appl Canc Res & Drug Discovery, Phoenix, AZ USA
[8] Sanofi, Global Oncol, Cambridge, MA USA
[9] Sanofi, Global Med Affairs, Cambridge, MA USA
[10] Sanofi, Res & Dev, Chilly Mazarin, France
[11] Sanofi, Res & Dev, Vitry Sur Seine, France
[12] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8029
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
    Dimopoulos, Meletios
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David
    Weisel, Katja
    Yang, Hui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Usmani, Saad Z.
    LANCET, 2020, 396 (10245): : 186 - 197
  • [22] Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma.
    Siegel, David Samuel DiCapua
    Weisel, Katja
    Zahlten-Kumeli, Anita
    Medhekar, Rohan
    Sapra, Sandhya
    Ding, Bifeng
    Leleu, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] EFFECT OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY LINE OF THERAPY: INTERIM RESULTS FROM THE PHASE 3 ASPIRE STUDY
    Dimopoulos, M. A.
    Stewart, A. K.
    Rajkumar, S. V.
    Masszi, T.
    Spicka, I.
    Oriol, A.
    Hajek, R.
    Rosinol, L.
    Siegel, D.
    Mihaylov, G. G.
    Goranova-Marinova, V.
    Rajnics, P.
    Suvorov, A.
    Niesvizky, R.
    Jakubowiak, A.
    San-Miguel, J.
    Ludwig, H.
    Zojwalla, N.
    Tonda, M.
    Yang, X.
    Moreau, P.
    Palumbo, A.
    HAEMATOLOGICA, 2015, 100 : 151 - 152
  • [24] Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone: Results from the Phase 3 Endeavor Study According to Age Subgroup
    Niesvizky, Ruben
    Ludwig, Heinz
    Spencer, Andrew
    Goldschmidt, Hartmut
    Pika, Tomas
    Mateos, Maria-Victoria
    Dimopoulos, Meletios A.
    Zhou, Lifen
    Kimballand, Amy S.
    Facon, Thierry
    BLOOD, 2017, 130
  • [25] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study(vol 396, 186, 2020)
    Dimopoulos, M.
    Quach, H.
    Mateos, M-, V
    Landgren, Ola
    Leleu, Xavier
    Siegel, David
    Weisel, Katja
    Yang, Hui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Usmani, Saad Z.
    LANCET, 2020, 396 (10249): : 466 - 466
  • [26] Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
    Stewart, A. Keith
    Rajkumar, S. Vincent
    Dimopoulos, Meletios A.
    Masszi, Tamas
    Spicka, Ivan
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David S.
    Mihaylov, Georgi G.
    Goranova-Marinova, Veselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej
    San Miguel, Jesus F.
    Ludwig, Heinz
    Zojwalla, Naseem
    Tonda, Margaret E.
    Xing, Biao
    Moreau, Philippe
    Palumbo, Antonio
    BLOOD, 2014, 124 (21)
  • [27] Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma
    Stewart, A. K.
    Rajkumar, S. V.
    Dimopoulos, M. A.
    Mihaylov, G. G.
    Goranova-Marinova, V.
    Rajnics, P.
    Suvorov, A.
    Jakubowiak, A. J.
    San-Miguel, J. F.
    Zojwalla, N.
    Moreau, P.
    Palumbo, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 20 - 20
  • [28] Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
    Mateos, Maria-Victoria
    Rodriguez Otero, Paula
    Koh, Youngil
    Martinez-Lopez, Joaquin
    Parmar, Gurdeep
    Prince, H. Miles
    Quach, Hang
    Ribas, Paz
    Hermansen, Emil
    Hungria, Vania T. M.
    Besisik, Sevgi Kalayoglu
    Kim, Jin Seok
    Leleu, Xavier
    Peceliunas, Valdas
    Schjesvold, Fredrik
    Sevindik, Omur G.
    Lavrova, Tatiana
    Dubin, Franck
    Devisme, Christine
    Lepine, Lucie
    Mace, Sandrine
    Morisse, Mony
    Ghobrial, Irene
    BLOOD, 2022, 140 : 7317 - 7319
  • [29] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
    Usmani, Saad Z.
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David S.
    Weisel, Katja
    Yang, Hui
    Klippel, Zandra K.
    Zahlten-Kumeli, Anita
    Dimopoulos, Meletios A.
    BLOOD, 2019, 134
  • [30] Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)
    Chng, Wee-Joo
    Goldschmidt, Hartmut
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Joshua, Douglas
    Palumbo, Antonio
    Facon, Thierry
    Ludwig, Heinz
    Pour, Ludek
    Niesvizky, Ruben
    Oriol, Albert
    Rosinol, Laura
    Suvorov, Aleksandr
    Gaidano, Gianluca
    Pika, Tomas
    Weisel, Katja
    Goranova-Marinova, Vesselina
    Gillenwater, Heidi H.
    Mohamed, Nehal
    Feng, Shibao
    Hajek, Roman
    BLOOD, 2015, 126 (23)
12345